Abstract 6P
Background
Development of an immunosuppressive pre-metastatic microenvironment is a prerequisite for lung metastasis of breast cancer. However, previous mechanisms have focused on immune cells rather than vascular endothelial cells. Our previous research has shown that tumor cell-released autophagosomes (TRAPs) preferentially reaches the lung rather than breast cancer cells in the mouse model. Could the pre-arrival of TRAPs promote the immunosuppressive pre-metastatic microenvironment by acting on endothelial cells?.
Methods
TRAPs-treated ECs were subjected to transcriptome analysis. T cell function was detected by flow cytometry after co-culture of TRAP-treated ECs with T cells in vitro. We injected TRAPs into mice via the tail vein or established endogenous Becn1 knockdown 4T1 tumor cells model which reduced TRAPs release. Flow cytometry will be used to analyze Immunosuppressive function of PVECs and the late lung metastases was monitored. Antibody blocking assay and HMGB1 knockdown cell lines were used to detect key DAMP on the surface of TRAPs. Inhibitor-treated ECs and TLR4 knockout mice were used to detect corresponding functional receptors on the surface of ECs. CD/FillpinⅢ/CPZ -treated ECs to detect the movement of the cytoskeleton. Activation of signal pathways was detected by Western blot.
Results
TRAPs from breast tumor cell lines stimulated the upregulation of PD-L1 in PVECs via a HMGB1-TLR4–MyD88–p38/STAT3 signal cascade and depended on the movement of the cytoskeleton of ECs. TRAPs-treated ECs suppressed IFN-γ secretion and proliferation of CD4+ and CD8+ T cells in vitro and in vivo. Anti-PD-L1 treatment upregulated pulmonary T-cell function and reduced lung metastasis in tumor-bearing mice.
Conclusions
These findings elucidate a novel role and mechanism of TRAPs-induced immunosuppression of vascular endothelial cells in the pre-metastatic microenvironment. TRAPs or their surface HMGB1 represent important therapeutic targets to reverse immunosuppressive formation, while also providing a new theoretical basis for the treatment of early breast cancer with PD-L1 antibodies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Y. Wu, X. Zhou, C. Wu.
Funding
National Natural Science Foundation, China.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
321P - Epidemiology and survival analysis of epithelial ovarian cancer: Results from comprehensive care center in north India
Presenter: Amit Badola
Session: Poster Display
Resources:
Abstract
322P - Evaluation of chemotherapy response score as a prognostic factor in advanced epithelial ovarian cancer: A prospective single centre study
Presenter: Upasana Palo
Session: Poster Display
Resources:
Abstract
323P - Platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio as prognostic biomarkers in ovarian cancer among the Asian population: A meta-analysis
Presenter: Wikania Wira Wiguna I Gede
Session: Poster Display
Resources:
Abstract
324P - All-<italic>trans</italic> retinoic acid sensitizes ovarian cancer to niraparib by inhibiting ALDH1A1 activity
Presenter: Bingjie Mei
Session: Poster Display
Resources:
Abstract
325TiP - A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS/KOV-HIPEC-04)
Presenter: Myong Cheol Lim
Session: Poster Display
Resources:
Abstract
327TiP - A single arm phase II study of single agent pemetrexed in platinum resistant/refractory epithelial ovarian or primary peritoneal cancer
Presenter: Swasthik Parampalli
Session: Poster Display
Resources:
Abstract
337P - Demographic patterns and survival outcomes of patients with T and NK-cell lymphoma at the National Cancer Centre Singapore
Presenter: Mohamed Haniffa Bin Hasan Mohamed
Session: Poster Display
Resources:
Abstract
338P - Multicenter real-world study of advanced-stage non-nasal type NK/T cell lymphoma (NKTCL): Clinical features, treatment and prognosis
Presenter: Yuce Wei
Session: Poster Display
Resources:
Abstract
339P - A comparison of survival of patients with relapsed or refractory diffuse large B cell lymphoma undergoing allogeneic stem cell transplantation or receiving CAR-T therapy
Presenter: Kenta Hayashino
Session: Poster Display
Resources:
Abstract
340P - The role of CT scans and laboratory tests for surveillance in patients with diffuse large B cell lymphoma who achieved complete remission after first-line chemotherapy
Presenter: YU Yagi
Session: Poster Display
Resources:
Abstract